Data Insights

Trastuzumab rezetecan by Jiangsu Hengrui Medicine for Solid Tumor: Likelihood of Approval

Trastuzumab rezetecan is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Solid Tumor. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Trastuzumab Rezetecan in Solid Tumor

Data Insights

Trastuzumab rezetecan by Jiangsu Hengrui Medicine for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval

Trastuzumab rezetecan is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Gastroesophageal (GE) Junction Carcinomas....

Likelihood of Approval and Phase Transition Success Rate Model - Trastuzumab Rezetecan in Gastroesophageal (GE) Junction Carcinomas

Data Insights

Trastuzumab rezetecan by Jiangsu Hengrui Medicine for Non-Small Cell Lung Cancer: Likelihood of Approval

Trastuzumab rezetecan is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Non-Small Cell Lung Cancer....

Likelihood of Approval and Phase Transition Success Rate Model - Trastuzumab Rezetecan in Non-Small Cell Lung Cancer

Data Insights

Trastuzumab rezetecan by Jiangsu Hengrui Medicine for Colorectal Cancer: Likelihood of Approval

Trastuzumab rezetecan is under clinical development by Jiangsu Hengrui Medicine and currently in Phase III for Colorectal Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Trastuzumab Rezetecan in Colorectal Cancer

Data Insights

Trastuzumab rezetecan by Jiangsu Hengrui Medicine for Metastatic Colorectal Cancer: Likelihood of Approval

Trastuzumab rezetecan is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Metastatic Colorectal Cancer. According...

Likelihood of Approval and Phase Transition Success Rate Model - Trastuzumab Rezetecan in Metastatic Colorectal Cancer

Data Insights

Trastuzumab rezetecan by Jiangsu Hengrui Medicine for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer): Likelihood of Approval

Trastuzumab rezetecan is under clinical development by Jiangsu Hengrui Medicine and currently in Phase III for Human Epidermal Growth Factor...

Likelihood of Approval and Phase Transition Success Rate Model - Trastuzumab Rezetecan in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer)

Data Insights

Trastuzumab rezetecan by Jiangsu Hengrui Medicine for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval

Trastuzumab rezetecan is under clinical development by Jiangsu Hengrui Medicine and currently in Phase III for Adenocarcinoma Of The Gastroesophageal...

Likelihood of Approval and Phase Transition Success Rate Model - Trastuzumab Rezetecan in Adenocarcinoma Of The Gastroesophageal Junction

Data Insights

Trastuzumab rezetecan by Jiangsu Hengrui Medicine for Gastric Cancer: Likelihood of Approval

Trastuzumab rezetecan is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Gastric Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Trastuzumab Rezetecan in Gastric Cancer

Data Insights

Trastuzumab rezetecan by Jiangsu Hengrui Medicine for Ovarian Cancer: Likelihood of Approval

Trastuzumab rezetecan is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Ovarian Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Trastuzumab Rezetecan in Ovarian Cancer